Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement

Circulation Journal

Volumn 74, Issue 9, 2010, Pages 1873-1879

  Ji, Qiang ^a   Mei, Yunqing ^a   Wang, Xisheng ^a   Feng, Jing ^a   Wusha, Dewei ^a   Cai, Jianzhi ^a   Sun, Yifeng ^a   Xie, Shiliang ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Angiotensin; Atrial fibrillation; Cardioversion; Rheumatic heart disease

Indexed keywords

AMIODARONE; IRBESARTAN;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART VALVE REPLACEMENT; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG EMBOLISM; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; SINUS RHYTHM; SURVIVAL; THYROID DISEASE; VALVULAR HEART DISEASE;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BIPHENYL COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HEART ATRIA; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RHEUMATIC DISEASES; TETRAZOLES; TREATMENT OUTCOME;

EID: 77956125633     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0254     Document Type: Article

References (22)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-1022.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
3. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009; 73: 2244-2249.
4. von Oppell UO, Masani N, O'Callaghan P, Wheeler R, Dimitrakakis G, Schiffelers S. Mitral valve surgery plus concomitant atrial fibrillation ablation is superior to mitral valve surgery alone with an intensive rhythm control strategy. Eur J Cardiothorac Surg 2009; 35: 641-650.
5. Sims JB, Roberts WC. Comparison of findings in patients with versus without atrial fibrillation just before isolated mitral valve replacement for rheumatic mitral stenosis (with or without associated mitral regurgitation). Am J Cardiol 2006; 97: 1035-1038.
6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
7. Friberg L, Hammar N, Edvardsson N, Rosenqvist M. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: Report from the Stockholm Cohort of Atrial Fibrillation (SCAF). Heart 2009; 95: 1000-1005.
8. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: A prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-920.
9. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-252.
10. Members of the Sicilian Gambit. New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. Eur Heart J 2001; 22: 2148-2163.
11. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
12. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
13. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. J Am Coll Cardiol 2006; 48: 2340-2347.
14. Schilling RJ. Cardioversion of atrial fibrillation: The use of antiarrhythmic drugs. Heart 2010; 96: 333-338.
15. Niwano S, Sasaki T, Kurokawa S, Kiryu M, Fukaya H, Hatakeyama Y, et al. Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG. Circ J 2009; 73: 1210-1218.
16. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with longlasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
17. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
18. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009; 29: 31-48.
19. Soran H, Ziglam H, Al-Najjar M, Younis N. The role of the renin angiotensin system blocking in the management of atrial fibrillation. Acta Cardiol 2008; 63: 457-465.
20. Healey JS, Morillo CA, Connolly SJ. Role of the renin-angiotensinaldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol 2005; 20: 31-37.
21. Birnie DH, Gollob M, Healey JS. Clinical trials, the renin angiotensin system and atrial fibrillation. Curr Opin Cardiol 2006; 21: 368-375.
22. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002; 105: 2672-2678.